Applied Clinical Trials
Medidata
Data correction rates are indicative of the overall quality of data during a clinical trial. A higher rate of data correction would indicate a lower quality of data being entered, which raises concerns over the accuracy of data being collected during the study,and also, the level of training of the site personnel with electronic data capture (EDC) systems or other aspects of the protocol. The training and comfort level site personnel have with EDC systems would also contribute toward timely entry of data during the conduct of the study. A longer duration of time between subject visits to actual entry into the EDC would delay important decisions that determine the course of the study and may even indirectly impact patient safety.
Figure 1
This month's Insights graph provides a comparative—and contextual—evaluation of trends in terms of data correction rates and the time from subject visit to eCRF entry. This data is derived from Phase II and III studies in the Medidata Insights metrics warehouse for the time period between 2007 and 2012. As evident from the graph, the data correction rate remains essentially flat while visit to data entry has a downward trend, with an almost 80% decrease during the time period. This clearly indicates that timely data entry does not necessarily translate to high initial data accuracy.
Interestingly, data correction rates also decreased 21% in 2012, from an all-time high at 6.6% in 2007. It remains to be seen if this downward shift in 2012 would usher a downward trend in the years to come. It is possible that any shift in data correction rates due to timely entry of data (as suggested by the downward trend), is masked by other factors such as increases in the complexity of both eCRFs and protocols. A decreasing trend in data entry time is an indicator of better overall use of EDC systems, which can be used to relay insightful information, during the course of a clinical trial. It also highlights the potential opportunity of business analytics solutions, which seamlessly gather data from EDC and other eClinical systems to serve as key drivers for better planning and monitoring of clinical trials.
What other factors do you think are impacting data correction rates? As always, Medidata is interested to hear your take on this result. Please stay tuned as the company delves further into the Insights metric data through 2012.
—Medidata Solutions, www.mdsol.com
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.